China Human Vaccine Industry Report, 2017-2021

Tuesday, July 25, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 24, 2017 /PRNewswire/ -- The human vaccine industry presented the following main characteristics in 2016 in China:

1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong, the country's lot release volume of human vaccines came to 553.6 million
doses through the year 2016, down 3.8% over the previous year. The lot release volume of ten vaccines (Hepatitis B vaccine, Diphtheria, Tetanus and acellular Pertussis combined vaccine (adsorbed), rabies vaccine, Japanese encephalitis vaccine, poliomyelitis vaccine, meningococcal vaccine, measles and rubella combined attenuated live vaccine, MMR combined attenuated live vaccine, influenza vaccine, and Hepatitis A Vaccine) was relatively higher, totaling 467.2 million doses, 84.4% of the country's total, a year-on-year 1.4% drop.Download the full report: https://www.reportbuyer.com/product/512477/2. The industry was highly concentrated.The Chinese human vaccine market had been highly concentrated, primarily dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products, Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, and Changchun Institute of Biological Products under China National Biotec Group Company Limited. In 2016, China National Biotec Group accounted for 52.6% of the country's lot release volume of human vaccines, compared with a small fraction of market share for Liaoning Chengda Biotechnology, Changsheng Bio-technology, Shenzhen Kangtai Biological Products, Chongqing Zhifei Biological Products, Beijing Minhai Biotechnology, Walvax Biotechnology, Changchun BCHT Biotechnology, Hualan Biological Engineering, Zhejiang Tianyuan Bio-Pharmaceutical, and Sinovac Biotech.3. Vaccine enterprises scaled up R&D efforts.Major Chinese vaccine enterprises have intensified their efforts for R&D in order to enhance overall competitiveness in recent years. Walvax Biotechnology has started HPV-2 industrialization project and is expected to launch the product in 2019, and meanwhile has put its 13-valent pneumococcal combined vaccine in phase III clinical trial and is predicted to bring the product to the market in 2018 or 2019. Launching of new vaccines will make the company more competitive. 4. Two-child policy, population aging, and new vaccines were drivers of the industry. Along with full implementation of the two-child policy in Oct 2015, the country's newborns increased sharply to 17.86 million in 2016 and will remain above 18 million each year over the next five years. Meanwhile, the population aged 60 and over reached 230.9 million by the end of 2016 and is expected to hit 245.3 million by 2021. In addition, some domestic enterprises have set about developing new vaccines like HPV vaccine and 13-valent pneumococcal vaccine which are expected to be available on the market in 2018 or 2019.Pushed by the two-child policy, population aging, and launching of new vaccines, the vaccine industry in China will grow rapidly with an estimated market size of up to RMB31.2 billion in 2021.China Human Vaccine Industry Report, 2017-2021 highlights the following:Human vaccine industry in China (operating environment, status quo, market demand, market size, circulation channel, import & export, competitive landscape, development trends, etc.);Analysis on Chinese human vaccine market segments(like Hepatitis B Vaccine, Meningococcal Vaccine, Hepatitis A vaccine, Influenza Vaccine, Hib Vaccine, Rabies Vaccine, Varicella Vaccine, Pneumococcal Vaccines, DTP Vaccine, Poliomyelitis Vaccine, Hepatitis E Vaccine), including market demand, lot release volume, competitive landscape, etc.;Download the full report: https://www.reportbuyer.com/product/512477/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/china-human-vaccine-industry-report-2017-2021-300493097.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook